Drug intelligence / Profile preview

AER005

Development stage: Preclinical
Lead developer: Aerium Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AER005 is a monoclonal antibody discovered by Julie Overbaugh at Fred Hutchinson Cancer Center and developed by Aerium Therapeutics. It targets a novel, highly conserved region of the SARS-CoV-2 spike protein outside the receptor-binding domain (RBD), providing broad neutralizing activity against previous and circulating variants. The antibody has been modified for extended half-life and potent activity, positioning it for potential inclusion in combination products like AER800 (AER003 + AER004) to enhance protection against viral evolution, particularly for immunocompromised patients.[1][7]

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on AER005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AER005.

Explore the full profile